Evidence map›Paper›PMID 39409079›Full record

ReviewInternational journal of molecular sciences2024

Current Overview of Spinocerebellar Ataxia Type 7 in Mexican Population: Challenges in Specialized Care for a Rare Disease.

César M Cerecedo-Zapata, Yessica S Tapia-Guerrero, José A Ramírez-González, Aranza Meza-Dorantes, Karla N Tercero-Pérez, Hernán Cortés, Araceli Guerra-Grajeda, Ilse H Ortega-Ibarra, Gabriela Gatica-Ramos, Alfredo Poblete-Velazquez and 4 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

César M Cerecedo-ZapataLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.
Yessica S Tapia-GuerreroLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.ORCID 0000-0003-3281-4757
José A Ramírez-GonzálezLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.ORCID 0000-0003-3715-1921
Aranza Meza-DorantesDepartment of Bioengineering, School of Engineering, Tecnologico de Monterrey, Campus Ciudad de México, Mexico City 14380, Mexico.
Karla N Tercero-PérezRehabilitation and Special Education Center of Veracruz (CRISVER), Xalapa de Enriquez 91097, Mexico.
Hernán CortésLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.ORCID 0000-0002-6147-4109
Araceli Guerra-GrajedaLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.ORCID 0000-0003-3442-1826
Ilse H Ortega-IbarraInstituto de Salud Pública, Universidad Veracruzana, Xalapa de Enriquez 91000, Mexico.
Gabriela Gatica-RamosInstituto de Salud Pública, Universidad Veracruzana, Xalapa de Enriquez 91000, Mexico.
Alfredo Poblete-VelazquezHospital Regional de Xalapa "Dr. Luis F. Nachón", Secretaria de Salud de Veracruz, Xalapa de Enriquez 91130, Mexico.
Norberto Leyva-GarcíaLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.
Luis Velázquez-PérezScience Cuban Academy, La Havana 12400, Cuba.
Bulmaro CisnerosDepartment of Genetics and Molecular Biology, Center of Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico.
Jonathan J MagañaLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City 14389, Mexico.ORCID 0000-0003-4399-4618

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a rare genetic disease characterized by progressive cerebellar syndrome and macular degeneration. In a previous study, we clinically and genetically characterized a group of Mexican patients, which represented one of the largest cohorts of SCA7 patients worldwide and demonstrated that all patients had a unique genetic origin. Our laboratory developed a program for the diagnosis, medical care, and long-term follow-up of these patients living in Veracruz State, and in this report, we present an update to this research, covering 2013 to 2024. So far, we identified 172 SCA7 carriers, with a few cases outside Veracruz, and our data support that the length of the CAG repeat tract mainly determines disease severity and life expectancy, and accordingly, we define three different phenotypes, early-onset (EO), classical-onset (CO), and late-onset (LO), with EO patients showing the lowest life expectancy. Furthermore, we found that parental transmission of mutant alleles leads to increased CAG repeat instability, compared to maternal ones. Interestingly, a haplotype analysis revealed that patients outside Veracruz may have different genetic origins. In conclusion, longitudinal observations of SCA7 patients provide insight into the natural history of SCA7 and help to design strategies for diagnosis, genetic counseling, physical rehabilitation, and therapeutic alternatives.

Indexed as

Rare DiseasesSpinocerebellar AtaxiasAge of OnsetHaplotypesHumansMexicoPhenotypeTrinucleotide Repeat ExpansionCAG repeatsgenetic testingMexican populationprevalencespinocerebellar ataxia type 7

Identifiers

PMID39409079
PMCPMC11476844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.